Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
Sjögren’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Sjögren’s Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Ratings: (0)|Views: 6|Likes:
Published by aarkstor

More info:

Published by: aarkstor on Jun 28, 2012
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOCX, PDF, TXT or read online from Scribd
See more
See less

12/23/2014

pdf

text

original

 
 
Sjögren’s Syndrome Therapeutics
- Pipeline Assessmentand Market Forecasts to 2019
Summary
company, the industry analysis specialist, has released its new report, “Sjögren’s Syndrome Therapeutics
-
Pipeline Assessment and Market Forecasts to 2019”.
The report is an essential source of information and
 
analysis on the global Sjogrens Syndrome Therapeutics market. The report identifies the key trends shaping
 
and driving the global Sjogrens Syndrome Therapeutics market. The report also provides insights on theprevalent competitive landscape and the emerging players expected to significantly alter the market
 
positioning of the current market leaders. Most importantly, the report provides valuable insights on thepipeline products within the global Sjogrens Syndrome Therapeutics sector. This report is built using data and
 
information sourced from proprietary databases, primary and secondary research and in-house analysis by
company’s team of industry experts.
 
 
Scope
 
The report provides information on the key drivers and challenges of the Sjogrens Syndrome Therapeuticsmarket. Its scope includes -
 
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Sjogrens SyndromeTherapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
 
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developedand emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
 
- Analysis of the current and future competition in the seven key countries Sjogrens Syndrome Therapeuticsmarket.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently
 
researched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the
 
implications for the Sjogrens Syndrome Therapeutics market.- Analysis of key recent licensing and partnership agreements in Sjogrens Syndrome Therapeutics market
 
Reasons to buy
 
The report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and
 
technologies and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global Sjogrens Syndrome
 
Therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and
 
companies likely to impact the global Sjogrens Syndrome Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by
 
analyzing the performance of various competitors.
 
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies togain a competitive advantage.
 
- Organize your sales and marketing efforts by identifying the market categories and segments that presentmaximum opportunities for consolidations, investments and strategic partnerships.
 
-
What’s the next big thing in the global Sjogrens Syndrome Therapeutics market landscape? –
Identify,understand and capitalize.1.1 List of Tables 51.2 List of Figures 6
 
2 Sjögren’s Syndrome Therapeutics
- Introduction 72.1 Overview 72.2 Epidemiology 7
 
2.3 Signs and Symptoms 72.3.1 Ocular Manifestation: 72.3.2 Oral Manifestation: 7
 
2.3.3 Systemic Manifestation: 7
 
2.4 Etiology 82.5 Pathophysiology 8
 
2.5.1 Cell Mediated 92.5.2 Inflammatory response 9
2.6 Diagnosis of Sjögren’s Syndrome 10
 
 
2.7 Treatment and Management Pattern: 112.8 company Pipeline Report Guidance 12
 
3 Sjögren’s Syndrome Therapeutics
- Market Characterization 133.1 Overview 133.2 Sjög
ren’s Syndrome Therapeutics Market Size (2006
-2011) - Global 13
3.3 Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - Global 14
 
3.4 Sjögren’s Syndrome Therapeutics Market Size (2006
-2011) - The US 15
 
3.5 Sjögren’s Syndrome Therapeutics Market F
orecast (2011-2019) - The US 16
3.6 Sjögren’s Syndrome Therapeutics Market Size (2006
-2011) - France 17
 
3.7 Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - France 18
3.8 Sjögren’s Syndrome Therapeutics Market Size (2006
-2011) - Germany 19
 
3.9
Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - Germany 20
3.10 Sjögren’s Syndrome Therapeutics Market Size (2006
-2011) - Italy 21
 
3.11 Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - Italy 22
 
3.12 Sjögren’s Syndrome Therapeuti
cs Market Size (2006-2011) - Spain 23
3.13 Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - Spain 24
 
3.14 Sjögren’s Syndrome Therapeutics Market Size (2006
-2011) - The UK 25
3.15 Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - The UK 26
 
3.16 Sjögren’s Syndrome Therapeutics Market Size (2006
-2011) - Japan 27
3.17 Sjögren’s Syndrome Therapeutics Market Forecast (2011
-2019) - Japan 28
 
3.18 Drivers and Barriers for the Sjögren’s Syndrome Therapeutics Market 29
 
 
3.18.1 Drivers for the S
 jögren’s Syndrome Therapeutics Market 29
 
3.18.2 Barriers for the Sjögren’s Syndrome Therapeutics Market 29
 
 
3.19 Key Events Impacting the Future Market 303.20 Opportunity and Unmet Need 30
 
3.21 Key Takeaway 31
4 Sjögren’s Syndrome Therapeutics
- Competitive Assessment 32
 
4.1 Overview 324.2 Strategic Competitor Assessment 32
 
4.3 Product Portfolio for Major Marketed Products in the Sjögren’s Syndrome Therapeutics Market 33
 
 
4.3.1 Stimulants 334.3.2 Disease Modifying Drugs (DMARDS) 35
 
4.3.3 Corticosteroids 354.3.4 Off- Label and Over the Counter Drugs 35
 
4.4 Key Takeaway 35
5 Sjögren’s Syndrome Therapeutics
- Pipeline Assessment 36
 
5.1 Overview 365.2 Strategic Pipeline Assessment 36
 
5.3 Sjögren’s Syndrome Pipeline
- Pipeline by Phases of Development 365.3.1
Sjögren’s Syndrome Therapeutics
- Phase III Pipeline 36
 
5.3.2 Sjögren’s Syndrome Therapeutics
- Phase II Pipeline 37
 
5.3.3 Sjögren’s Syndrome Therapeutics
- Phase I Pipeline 37
5.4 Sjögren’s Syndrome Pipeline by Mechanism of Action 38
 
 
5.5 Sjögren’s Syndro
me Technology Trends Analytical Framework 39
5.6 Sjögren’s Syndrome Therapeutics
- Promising Drugs under Clinical Development 41
 
5.7 Molecule Profile for Promising Drugs under Clinical Development 415.7.1 P-552-02 415.8 Key Takeaway 42
6 Sjögren’s Syndro
me Therapeutics - Clinical Trials Mapping 43
 
6.1 Clinical Trials by Country (US, EU5 and Japan) 43
 
6.2 Clinical Trials by Phase 446.3 Clinical Trials by Trial Status 45
 
6.4 Overall Sponsors 466.5 Prominent Sponsors 47
 
6.6 Top Companies Participating in S
 jögren’s Syndrome Therapeutics Clinical Trials 48
 
 
7 Sjögren’s Syndrome Therapeutics
- Strategic Assessment 497.1 Future Market Competition Scenario 49
 
8 Sjögren’s Syndrome Therapeutics
- Future Players 50
 
8.1 Introduction 508.2 Parion Sciences 508.3 Kainos Medicine, Inc. 51
 
9 Sjögren’s Syndrome Therapeutics
- Licensing and Partnership Deals 52
 
10 Sjögren’s Syndrome Therapeutics
- Appendix 5310.1 Definitions 5310.2 Abbreviations 5310.3 Methodology 54
 
10.3.1 Coverage 5410.3.2 Secondary Research 55
 
10.3.3 Forecasting 5510.3.4 Primary Research 58
 
10.3.5 Expert Panel Validation 58
 
10.4 Contact Us 5810.5 Disclaimer 5810.6 Bibliography 591.1 List of TablesTable 1: American-
European Revised Consensus Criteria for Sjögren’s Syndrome 10
 
 
Table 2: Sjögren’s
Syndrome Therapeutics Market, Global, Revenue ($m), 2006 - 2011 13
Table 3: Sjögren’s Syndrome Therapeutics Market, Global, Forecast ($m), 2011
- 2019 14
 
Table 4: Sjögren’s Syndrome Therapeutics Market, The US, Revenue ($m), 2006
-2011 15
Table 5: Sjögren’ 
s Syndrome Therapeutics Market, The US, Forecast ($m), 2011-2019 16
 
Table 6: Sjögren’s Syndrome Therapeutics Market, France, Revenue ($m), 2006
-2011 17
 
Table 7: Sjögren’s Syndrome Therapeutics Market, France, Forecast ($m), 2011
-2019 18
Table 8: Sjögren’s
Syndrome Therapeutics Market, Germany, Revenue ($m), 2006-2011 19
 
Table 9: Sjögren’s Syndrome Therapeutics Market, Germany, Forecast ($m), 2011
-2019 20
Table 10: Sjögren’s Syndrome Therapeutics Market, Italy, Revenue ($m), 2006
-2011 21
 
Table 11: Sjögren’s
Syndrome Therapeutics Market, Italy, Forecast ($m), 2011-2019 22
Table 12: Sjögren’s Syndrome Therapeutics Market, Spain, Revenue ($m), 2006
-2011 23
 
Table 13: Sjögren’s Syndrome Therapeutics Market, Spain, Forecasts ($m), 2011
-2019 24
Table 14: Sjögren’s S
yndrome Therapeutics Market, The UK, Revenue ($m), 2006-2011 25
 
Table 15: Sjögren’s Syndrome Therapeutics Market, the UK, Forecasts ($m), 2011
-2019 26
 
Table 16: Sjögren’s Syndrome Therapeutics Market, Japan, Revenue ($m), 2006
-2011 27
Table 17: Sjögren’s S
yndrome Therapeutics Market, Japan, Forecasts ($m), 2011-2019 28
 
Table 18: Salagen Clinical Study Details 33Table 19: Evoxac Clinical Study Details 34
 
Table 20: Sjögren’s Syndrome Therapeutics
- Phase III Pipeline, 2011 36
Table 21: Sjögren’s Syndrome The
rapeutics - Phase II Pipeline, 2011 37
 
Table 22: Sjögren’s Syndrome Therapeutics
- Phase I Pipeline, 2011 37
 
Table 23: Sjögren’s Syndrome Therapeutics
- Promising Drugs Under Clinical Development, 2011 41
Table 24: Sjögren’s Syndrome Therapeutics
- Clinical Trials by Country, 2011 43
 
Table 25: Sjögren’s Syndrome Therapeutics
- Clinical Trials by Phase, 2011 44
Table 26: Sjögren’s Syndrome Therapeutics
- Clinical Trials by Status, 2011 45
 
Table 27: Sjögren’s Syndrome Therapeutics
- Overall Sponsors, 2011 46
Table 28: Sjögren’s Syndrome Therapeutics
- Prominent Sponsors, 2011 47
 
Table 29: Sjögren’s Syndrome Therapeutics
- Top Companies Participating in Therapeutics Clinical Trials, 201148Table 30: Parion Sciences -
Sjögren’s Syndrome Therapeutics Pipeline, N
ovember 2011 50
 
Table 31: Parion Sciences -
Sjögren’s Syndrome Therapeutics Pipeline, November 2011 50
 Table 32: Kainos Medicine, Inc. -
Sjögren’s Syndrome Therapeutics Pipeline, November 2011 51
 
 
Table 33: Kainos Medicine, Inc.-
Sjögren’s Syndrome Therapeu
tics Pipeline, November 2011 511.2 List of Figures
 
Figure 1: Secretory Function in Unaffected People 9
 
Figure 2: Algorithm for the Treatment and Management of Sjögren’s Syndrome 11
 
Figure 3: Sjögren’s Syndrome Therapeutics Market, Global, Revenue ($m), 2
006 - 2011 13
 
Figure 4: Sjögren’s Syndrome Therapeutics Market, Global, Forecast ($m), 2011
- 2019 14
Figure 5: Sjögren’s Syndrome Therapeutics Market, The US, Revenue ($m), 2006
-2011 15
 
Figure 6: Sjögren’s Syndrome Therapeutics Market, The US, Forecast ($
m), 2011-2019 16
 
Figure 7: Sjögren’s Syndrome Therapeutics Market, France, Revenue ($m), 2006
-2011 17

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->